Purpose: There is a paucity of data on SBRT to non-spine bone (NSB) lesions compared to spine metastases. We report local recurrence (LR), widespread progression (WSP), and overall survival (OS) for oligometastatic patients treated to bone lesions with SBRT and investigate the hypothesis that outcomes are different between patients with spine and non-spine bone oligometastatic disease.
Methods: Patients with oligometastatic disease (≤5 cumulative extracranial metastases) treated with bone SBRT at 6 international institutions from 2007 to 2016 were reviewed. Fine and Gray competing risks and Cox regressions were used to analyze univariable and multivariable relationships between disease/treatment factors and outcomes.
Results: In total, 288 spine and 233 NSB lesions are reported in 356 patients. Cumulative incidence of LR across all bone lesions was 6.3%, 12.6% and 19.3% at 6 mo, 1 yr and 2 yrs. While univariable analysis suggested inferior LC and OS in spine patients, this did not hold true in multivariable analysis. The final regression model for LR in NSB lesions included PTV ≥ median of 31.8 cc (HR 5.02, p = 0.014) and primary histology, with RCC and NSCLC conferring a 10.8- and 6.5-fold increased risk of LR compared to prostate histology, respectively. The spine LR model included radioresistant histology (HR 2.11, p = 0.0051), PTV Dmin (BED10) ≥ median of 19.1 Gy (HR 0.46, p = 0.0085), and epidural disease (HR 1.99, p = 0.016).
Conclusion: This large multi-institutional series reports comparably excellent response to SBRT for a balanced distribution of oligometastatic NSB and spine lesions. Dose escalation for large and/or radioresistant NSB lesions should be explored, given the typical lack of an immediately adjacent dose-limiting critical structure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.radonc.2021.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Vaginal Microbiota, Human Papillomavirus Infection, and Cervical Carcinogenesis: A Systematic Review in the Latina Population.
J Epidemiol Glob Health
June 2024
Department of Basic Medical Sciences, University of Arizona College of Medicine-Phoenix, 425 N. 5th Street, Phoenix, AZ, 85004-2157, USA.
Background: Latina women experience disproportionately higher rates of HPV infection, persistence, and progression to cervical dysplasia and cancer compared to other racial-ethnic groups. This systematic review explores the relationship between the cervicovaginal microbiome and human papillomavirus infection, cervical dysplasia, and cervical cancer in Latinas.
Methods: The review abides by the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.
Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy.
Abdom Radiol (NY)
June 2023
Department of Urology, Peking University First Hospital, No.8 Xishiku St. Xicheng District, Beijing, China.
Purpose: To investigate the effects of various prostate biopsy protocols with reduced cores on the detection of clinically significant prostate cancer (csPCa) in individuals with MRI-visible lesions (Prostate Imaging Reporting and Data System ≥ 3).
Methods: A total of 464 patients with MRI-visible lesions were recruited. All patients underwent two or more targeted biopsies (TB) and systematic biopsies (SB).
An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases.
Radiother Oncol
November 2021
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, United States. Electronic address:
Purpose: There is a paucity of data on SBRT to non-spine bone (NSB) lesions compared to spine metastases. We report local recurrence (LR), widespread progression (WSP), and overall survival (OS) for oligometastatic patients treated to bone lesions with SBRT and investigate the hypothesis that outcomes are different between patients with spine and non-spine bone oligometastatic disease.
Methods: Patients with oligometastatic disease (≤5 cumulative extracranial metastases) treated with bone SBRT at 6 international institutions from 2007 to 2016 were reviewed.
Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?
Prostate Cancer Prostatic Dis
December 2020
The Department of Urology, Peking University First Hospital, 100034, Beijing, China.
Background: Due to the discomfort and incidence of complications increases with the increasing number of biopsy cores, the protocol of prostate biopsy has been promoted from systematic biopsy (SB) to targeted biopsy (TB) in many studies. However, the optimal prostate sampling scheme to balance the incidence of biopsy complications and accuracy of biopsy remains controversial. Our objective is to explore an optimal prostate cancer (PCa) sampling scheme with fewer SB cores.
View Article and Find Full Text PDFVariability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.
Radiology
July 2020
From the Departments of Radiology and Biomedical Imaging (A.C.W., R.J.Z.), Urology (A.C.W., P.R.C.), and Epidemiology and Biostatistics (C.E.M.) and the Clinical and Translational Science Institute (C.E.M.), University of California, San Francisco, 505 Parnassus Ave, M-392, Box 0628, San Francisco, CA 94143; Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pa (J.M.A., R.B.P.); Departments of Radiology and Radiological Sciences (S.A., V.G.B) and Urologic Surgery (S.A.), Vanderbilt University Medical Center, Nashville, Tenn; Departments of Radiology (A.O.) and Urology (N.S.B), University of Chicago, Chicago, Ill; Departments of Radiology (J.O.B) and Nuclear Medicine (J.J.F.), Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; Departments of Diagnostic Radiology (T.K.B., D.M.G), Interventional Radiology (S.E.M.), and Urology (J.F.W.), University of Texas MD Anderson Cancer Center, Houston, Tex; Diagnósticos da América S/A, Rio de Janeiro, Brazil (L.K.B); and Department of Radiology, Fluminense Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (L.K.B.); Department of Radiology, University of California, San Diego, San Diego, Calif (M.T.B., M.E.H.); UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, Calif (P.R.C.); Department of Radiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill (D.D.C., A.R.W.); Department of Radiology, University of British Columbia, Vancouver, Canada (S.D.C., R.D.); Department of Diagnostic Radiology, Oregon Health Science University, Portland, Ore (F.V.C., B.R.F.); Department of Radiology, University of New Mexico Health Sciences Center, Albuquerque, NM (S.C.E., B.S., J.B.S.); and Department of Radiology, Mayo Clinic, Rochester, Minn (A.T.F.). Joint Department of Medical Imaging, University Health Network-Mount Sinai Hospital-Women's College Hospital, Toronto, Canada (M.R.G., S.G.); Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wis (L.M.G.); Departments of Radiology (R.T.G.) and Surgery (R.T.G., T.J.P.), Duke University Medical Center and Duke Cancer Institute, Durham, NC; Department of Radiological Sciences and Urology, University of California, Irvine, Orange, Calif (R.H.); Virginia Commonwealth University School of Medicine, Richmond, Va (C.K.); Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (C.K.K.); Department of Radiology, University of Florida College of Medicine, Jacksonville, Fla (C.L.); Department of Radiology, Weill Cornell Medicine, New York, NY (D.J.A.M.); Department of Radiology, University of Colorado at Denver, Denver, Colo (N.U.P.); Molecular Imaging Program (B.T.) and Urologic Oncology Branch (P.A.P.), National Cancer Institute, National Institutes of Health, Bethesda, Md; Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center, Houston, Tex (V.S.T.); Departments of Radiology (A.B.R.) and Urologic Oncology (S.S.T.), New York University Langone Health, New York, NY; Department of Radiology, University of Cincinnati Medical Center, Cincinnati, Ohio (S.V.); Department of Urology, University of Minnesota Institute for Prostate and Urologic Cancers, Minneapolis, Minn (C.A.W.); and Department of Radiology, Virginia Commonwealth University, Richmond, Va (J.Y.).
Background Prostate MRI is used widely in clinical care for guiding tissue sampling, active surveillance, and staging. The Prostate Imaging Reporting and Data System (PI-RADS) helps provide a standardized probabilistic approach for identifying clinically significant prostate cancer. Despite widespread use, the variability in performance of prostate MRI across practices remains unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!